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Although MRI resolution does not yet match that of CT, MRI can play an important role for
functional imaging in patients with ILD. MRI can differentiate between inflammatory and fibrotic
changes for monitoring targeted therapy in patients with ILD. http://ow.ly/uicr30myy9z
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ABSTRACT Thin-slices multi-detector computed tomography (MDCT) plays a key role in the
differential diagnosis of interstitial lung disease (ILD). However, thin-slices MDCT has a limited ability to
detect active inflammation, which is an important target of newly developed ILD drug therapy. Magnetic
resonance imaging (MRI), thanks to its multi-parameter capability, provides better tissue characterisation
than thin-slices MDCT.
Our aim was to summarise the current status of MRI applications in ILD and to propose an ILD-MRI
protocol. A systematic literature search was conducted for relevant studies on chest MRI in patients with ILD.
We retrieved 1246 papers of which 55 original papers were selected for the review. We identified 24
studies comparing image quality of thin-slices MDCT and MRI using several MRI sequences. These
studies described new MRI sequences to assess ILD parenchymal abnormalities, such as honeycombing,
reticulation and ground-glass opacity. Thin-slices MDCT remains superior to MRI for morphological
imaging. However, recent studies with ultra-short echo-time MRI showed image quality comparable to
thin-slices MDCT. Several studies demonstrated the added value of chest MRI by using functional
imaging, especially to detect and quantify inflammatory changes.
We concluded that chest MRI could play a role in ILD patients to differentiate inflammatory and
fibrotic changes and to assess efficacy of new ILD drugs.
Copyright ©ERS 2018. ERR articles are open access and distributed under the terms of the Creative Commons
Attribution Non-Commercial Licence 4.0.
This article has supplementary material available from err.ersjournals.com
Provenance: Submitted article, peer reviewed.
Received: July 21 2018 | Accepted after revision: Oct 23 2018




Interstitial lung disease (ILD) includes a large group of diffuse parenchymal lung diseases that are grouped
together because of similar clinical, pathological and radiological features [1].
The most frequent radiological patterns are usual interstitial pneumonia (UIP) and nonspecific
interstitial pneumonia (NSIP) patterns. While in UIP the key feature is honeycombing [2], on
thin-slices multi-detector computed tomography (MDCT) for NSIP the key feature is bilateral
ground-glass opacity [1]. Despite thin-slices MDCT conveying the highest diagnostic confidence in
ILD, the diagnosis is frequently only achieved in a multidisciplinary meeting by combining clinical,
radiological and pathological information [3, 4]. Thin-slices MDCT is especially limited on defining
areas of active inflammation [5]. As a matter of fact, area of inflammation and fibrosis can have the
same ground-glass opacity appearance on thin-slices MDCT [5, 6]. Hence, thin-slices MDCT cannot
distinguish between pure inflammatory and fibrotic ground-glass opacity, limiting its ability to detect
active inflammation areas in secondary UIP or more fibrotic NSIP patients. This differentiation is
important in the treatment of ILD, because anti-inflammatory medications (i.e. corticosteroids) are
currently used in ILD related to collagen vascular disease in contrary to the antifibrotics pirfenidone
(Roche, Basel, Switzerland) and nintedanib (Boehringer Ingelheim, Ingelheim am Rhein, Germany),
which are indicated in patients with idiopathic pulmonary fibrosis (IPF) [7, 8]. Thin-slices MDCT is
also limited by poor reproducibility of visual scores for ILD abnormalities and lack of specific
outcome measures to evaluate response to treatment [9]. Recently, quantitative thin-slices MDCT
scoring systems have improved the sensitivity of thin-slices MDCT to monitor ILD, but they are still
used in the research setting [10]. For these reasons, in clinical practice, pulmonary function tests
(PFT) remain the gold standard for monitoring ILD patients, especially by using the diffusing
capacity of the lung for carbon monoxide (DLCO) and forced vital capacity (FVC). However, PFT only
provide a global assessment of lung function, and they cannot track regional changes of ILD [1].
Moreover, both FVC and DLCO have low sensitivity and marginal changes in the range of 5–10% are
difficult to interpret. Therefore, it is clear that there is a great need for a sensitive clinical and imaging
tool to monitor ILD progression and response to treatment [11].
Magnetic resonance imaging (MRI) may overcome the limitations of computed tomography and PFT.
When compared to thin-slices MDCT for image quality, chest MRI does not provide any additional
information [12]. However, the main advantage of MRI is the ability to provide functional and
structural information in a single examination [13, 14]. New chest MRI techniques have recently been
developed and can provide information about ventilation, inflammation, perfusion and structure which
could be useful to improve assessment of ILD progression and prediction of response to ILD drug
therapy [15].
To date, the limited use of MRI in ILD is related to the challenges posed by this technique, with poor
signal-to-noise ratio (SNR) related to physical properties of the pulmonary parenchyma and long scan
time [16]. However, recent technical advances, such as parallel imaging, multi-array phase coils and
ultra-short echo-time techniques have enabled higher image quality and shorter scan time [17]. These
improvements have allowed chest MRI to emerge as an alternative imaging modality for the
assessment of pulmonary diseases both in children and adults [16, 18]. Currently, chest MRI serves as
a research tool for ILD, but it might play an important role in the near future in ILD therapeutics and
monitoring. In addition to the obvious advantage of the absence of ionising radiation, chest MRI may
allow higher tissue characterisation and differentiation between inflammatory and pure fibrotic
ground-glass opacity [12–15, 18]. The primary aim of this systematic review was to summarise the
current status and progress of MRI application in ILD. The most important articles published in the
past two decades were reviewed to describe all possible applications of chest MRI in ILD. The review
focuses on the potential role of MRI on ILD and emphasises the open questions that future research
studies will have to address. Finally, we proposed an MRI protocol for ILD (M-ILD) to address these
research questions.
Methods
A systematic literature search was conducted in collaboration with experienced medical librarians on the
application of chest MRI in patients with ILD. We searched Embase, Medline, Web of Science, Scopus,
Cochrane, Google scholar and PubMed databases for relevant publications. The last search was run on
January 01, 2018. Key words included: chronic lung disease OR interstitial lung disease OR ILD OR UIP
OR NSIP AND magnetic resonance imaging AND MRI. Titles and abstracts were screened by two
independent reviewers (C. Romei and L. Turturici). We only included articles published in English that
described original research and addressed chest MRI findings in patients with ILD. Reference lists of
included articles were reviewed for additional references.
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Results
In total 1246 articles were retrieved. Figure 1 shows the flowchart for all harvested papers. Finally, 49
articles met the inclusion criteria and six additional articles were retrieved from their reference lists. We
excluded 31 technical articles regarding specific chest MRI techniques. In total, we included 24 original
articles (supplementary table 1). Year of publication varied from 1996 to 2017. Articles described several
ILD patterns and groups of diseases using different diagnostic criteria for ILD. The results of these studies
are grouped by MRI technique and presented according to their clinical availability, from those applicable
in daily practice to the most advanced techniques performed in a research setting.
Morphological imaging
Thin-slices MDCT remains the gold standard to detect structural ILD abnormalities, such as ground-glass
opacity, reticulation, honeycombing and traction bronchiectasis [9]. Thanks to the development of new
MRI techniques, sequences have become available that can be useful for evaluating ILD abnormalities
(figure 2) [18–20]. Several studies have compared sensitivity and specificity of thin-slices MDCT to MRI
to assess ILD abnormalities [21]. The first sequence evaluated for morphological ILD imaging was a
single-shot fast spin echo (Half-Fourier Single-shot Turbo Spin-Echo (HASTE); Siemens, Erlangen,
Germany) T2-weighted acquisition. HASTE images provide high-signal intensity in water-rich tissues;
therefore, lung abnormalities appear bright and surrounded by air-filled parenchyma with low-signal
intensity. HATABU et al. [22] showed that breath-hold HASTE sequences were of diagnostic quality in 20
patients with several lung diseases, including interstitial abnormalities such as ground-glass opacity and
bronchiectasis. PUDERBACH et al. [23] also used HASTE before and after contrast agent administration in
patients with cystic fibrosis and demonstrated a moderate agreement with thin-slices MDCT. The
concordance of chest MRI related to thin-slices MDCT to define the severity of bronchiectasis,
peribronchial wall thickening, bullae and emphysema were 57%, 73%, 77% and 80%, respectively [23].
HEKIMOGLU et al. [24] tested HASTE in patients with progressive massive fibrosis and found a significant
agreement between MRI and thin-slices MDCT findings with an intraclass correlation coefficient (ICC) of
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FIGURE 1 Flow chart of all the harvested papers. MRI: magnetic resonance imaging; ILD: interstitial lung
disease.
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respiratory and cardiac motion artefacts [24]. PINAL-FERNANDEZ et al. [25] evaluated the utility of HASTE
to assess the extent of ILD involvement in patients with systemic sclerosis. HASTE showed a good
diagnostic performance to detect ILD with an area under the curve of 96% (95% CI 89–100%). This study
demonstrated that HASTE MRI could detect patients with >0.5% ILD extent with a sensitivity of 93% and
specificity of 100%. Furthermore, MRI showed the same diagnostic performance (p=0.03) of thin-slices
MDCT to detect ILD in systemic sclerosis patients [25]. RAJARAM et al. [26] retrospectively analysed chest
MRI of 224 patients, acquired using a two-dimensional balanced steady-state free-precession (bSSFP)
sequence. bSSFP sequence provides a mixed weighting T2/T1 with fast acquisition that freezes respiratory
and cardiac motion allowing acquisitions of the entire thorax in a single breath-hold [16]. Compared to
thin-slices MDCT, the sensitivity and specificity of MRI in the identification of pulmonary fibrosis were
89% (95% CI 77–96%) and 91% (95% CI 76–98%). However, MRI only revealed 75% of ground-glass
opacity, 67% of traction bronchiectasis and 45% of cystic reticular changes detected with thin-slices
MDCT. MRI was even less effective in depicting emphysema (16%) and minor fibrosis (67%), although








FIGURE 2 Comparison of radiological findings of interstitial lung disease with thin-slices multi-detector
computed tomography (MDCT) and magnetic resonance imaging (MRI). Honeycombing at a) thin-slices MDCT
and b) MRI two-dimensional axial PROPELLER T2-weighted sequence in a 78-year-old female with secondary
usual interstitial pneumonia from collagen vascular disease. The magnified images of MDCT (a1) and MRI
(b1) show honeycombing (black arrow) and the area of ground-glass opacity (white arrow). The high signal of
ground-glass opacity might be due to water content and therefore indicates active inflammation. Ground-glass
opacity at c) thin-slices MDCT and d) MRI sagittal reformat three-dimensional SPGR proton density-weighted
sequence pre-contrast in a 62-year-old male with idiopathic pulmonary fibrosis. On the magnified images of
MDCT (c1) and MRI (d1), the ground-glass opacity is harder to identify on MRI (white arrow) than on MDCT
(black arrow). Reticulation at e) thin-slices MDCT and f) MRI coronal reformat three-dimensional SPGR after
T1-weighted contrast-enhanced administration (at 20 min) in a 78-year-old female with secondary usual
interstitial pneumonia from collagen vascular disease. In the magnified images of MDCT (e1) and MRI (f1) the
different appearance of reticulation on MRI (white arrow) and MDCT (black arrow) is probably due to both a
different breathing condition (MDCT inspiration versus MRI expiration) and slice thickness (MDCT 1 mm versus
MRI 3 mm).
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utility of bSSFP in the evaluation of the severity of pulmonary fibrosis in an unselected group of patients.
Although bSSFP and HASTE sequences were not directly compared, the authors underlined the
advantages of bSSFP over HASTE due to a shorter echo and acquisition times, lower sensitivity to motion
artefacts and mixed T2/T1 contrast weighting [23].
Other gradient echo-based sequences, such as the spoiled gradient echo sequences (SPGR; GE Healthcare,
Milwaukee, WI, USA) and Volume Interpolated Breath-hold Examination (VIBE; Siemens), are usually
performed as non-contrast acquisitions with a proton density weighting to enhance SNR. They are
particularly suited to assess bulky consolidations and large areas of fibrosis in inspiration and to detect
trapped air in expiration [16]. However, in the reviewed literature, we did not find any applications of this
technique for ILD, but only in other small airways diseases [17]. T1-weighted gradient-echo imaging is
usually combined with contrast administration to enhance parenchymal visualisation. In the reviewed
literature, post-contrast T1-weighted imaging has been mostly used to assess pattern of enhancement of
fibrotic tissue, therefore we will discuss it along with the post-contrast imaging techniques in a later section.
Currently, the most promising MRI sequences to evaluate lung abnormalities using MRI are the
ultra-short echo-time sequences [27]. Ultra-short echo-time limits signal decay thanks to echo-time in the
range of microseconds instead of milliseconds providing high SNR and high-resolution images. Image
quality of ultra-short echo-time has been described to be almost comparable to thin-slices MDCT [28]. In
a study of OHNO et al. [12] ultra-short echo-time was compared to thin-slices MDCT to assess ILD
findings in 19 patients. To diagnose ILD, ultra-short echo-time showed an overall sensitivity, specificity
and accuracy of 100.0%, 97.0% and 97.6%, respectively. However, to evaluate each abnormality
individually, such as reticulation, bronchiectasis, ground-glass opacity and honeycombing, thin-slices
MDCT showed higher sensitivity, specificity and accuracy than ultra-short echo-time. For instance, to
define reticulation, thin-slices MDCT has a sensitivity, specificity and accuracy of 87.2%, 96.4% and 95.6%,
respectively, compared to ultra-short echo time that was 71.4%, 94.4% and 92.8%. A current limitation of
ultra-short echo-time is the data acquisition in free-breathing end-respiratory conditions, which can
determine underestimation of the severity of airways disease in ILD patients. With thin-slices MDCT, ILD
is routinely assessed with end-inspiratory breath-hold scans in supine and prone positions, for a better
definition of reticulation and honeycombing [29]. These different breathing conditions could have
contributed to the different performance of ultra-short echo-time compared to thin-slices MDCT in the
study of OHNO et al. [12]. To date, ultra-short echo-time has only been tested in research settings,
therefore larger validation studies with multicentre ILD cohorts are needed to confirm these promising
results [12].
Functional imaging
Although thin-slices MDCT remains superior to MRI to assess structural changes in ILD, several
functional MRI techniques might play a complementary role in ILD. Ventilation techniques without and
with gaseous contrasts could provide important information regarding ventilation mismatch in ILD
patients [30]. Active lung inflammatory tissue could be assessed with T2-weighted sequences or using
diffusion weighted imaging (DWI) [31]. Perfusion studies with non-contrast and contrast-enhanced MRI
techniques could be used to quantify the amount of lung fibrosis [13]. Eventually, dynamic MRI could
have a role in quantifying diaphragm mechanics and progressive lung fibrosis of ILD patients [16].
These techniques will be briefly described below, starting with those clinically available to the most
experimental techniques. When available, results of studies using the described MRI technique will be
presented.
Ventilation
For direct lung ventilation imaging with magnetic resonance, several techniques are available. They either
rely on oxygen enhancement, hyperpolarised noble gases or Fourier decomposition [32–34]. The
oxygen-enhanced MRI can be applied to assess regional ventilation, alveolar–capillary gas transfer of
molecular oxygen, oxygen uptake per respiratory cycle and airflow limitation [35, 36]. This method uses the
paramagnetic effect of pure oxygen to shorten T1 relaxation times, leading to a signal enhancement [37].
Several studies have tested oxygen-enhanced MRI in patients with ILD. MOLINARI et al. [32]
demonstrated a statistically significant correlation between oxygen-enhanced MRI and PFTs in patients
with UIP (n=1), NSIP (n=8) and sarcoidosis (n=1). STADLER et al. [38] showed a shortening of the T1
relaxation time in patients with lung fibrosis, suggesting that T1 measurements could be used to monitor
disease progression and quantify the amount of lung fibrosis. Furthermore, STADLER et al. [39, 40], using
T1 maps, investigated how the breathing status influenced T1 values of the lung parenchyma and
demonstrated a statistically significant difference of inspiratory T1 values in comparison to expiratory ones
both in healthy individuals [39] and patients with emphysema and fibrosis [40]. Moreover, both
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pathological groups showed lower average T1 values in inspiration and expiration compared to healthy
individuals while the average expiratory T1 was significantly higher in the fibrosis group than the
emphysema group [40].
OHNO et al. [41] found that oxygen-enhanced MRI was comparable to thin-slices MDCT to determine
pulmonary functional loss and disease severity in ILD patients with connective tissue disease.
Oxygen-enhanced MRI is a cheap and safe technique, but so far it has been performed in small groups of
patients and in research settings, because, it remains quite challenging with long scan acquisitions and
poor SNR [42]. Hyperpolarised gas-MRI, using helium (3He) or xenon (129Xe) as gaseous contrasts
provides quantitative regional information on pulmonary ventilation and lung microstructure changes [43].
Currently, hyperpolarised gas-MRI has not been used in ILD. Hyperpolarised gas-MRI provides
high-image quality and high SNR [42, 44]. Despite its established role for imaging lung function, the
complicated process of hyperpolarisation of the noble gases, the high costs, in particular for 3He, and the
need of dedicated hardware has, so far, precluded the translation of this technology to the clinic [42].
Hopefully in the future, hyperpolarised xenon-MRI will be made available as a diagnostic and therapeutic
monitoring tool for lung-related diseases, including ILD. To date, no studies have been conducted in ILD
with fluorinated gas MRI, a new technique that provides high-quality ventilation imaging similar in quality
to those from hyperpolarised gas-MRI.
Contrast-enhanced techniques
Contrast-enhanced thin-slices MDCT is not routinely used in ILD, because iodine contrast does not
increase the sensitivity or specificity to detect and characterise ILD abnormalities. However, contrast
determines a significant increase of radiation exposure in patients [45].
Contrast-enhanced magnetic resonance perfusion, thanks to its ability to characterise different tissues,
could represent a potential alternative in clinical practice. MRI for myocardial fibrosis detection, using
specific late contrast-enhanced sequences, is a well-validated technique routinely used in cardiac imaging.
As matter of fact, gadolinium-based contrast agent (GBCA) washes out from normal tissue while it
remains in fibrotic tissue. This characteristic was used by LAVELLE et al. [46] to detect and characterise
pulmonary fibrosis. In this study, a specific double inversion-recovery gradient echo-pulse sequence was
used to null the pulmonary arterial blood signal and depict pulmonary fibrosis with late-enhanced MRI.
LAVELLE et al. [46] demonstrated that the extent of pulmonary fibrosis on late-enhanced MRI correlated
significantly with thin-slices MDCT (r=0.78, p<0.001). However, the percentage of reticulation or
honeycombing showed no significant correlations between the two modalities (p=0.34 and p=0.23,
respectively). MIRSADRAEE et al. [47] evaluated T1 signal characteristics in the fibrotic lung parenchyma
pre- and post-contrast injection at 10 and 20 min. At 10 min after contrast injection, normal lung of
healthy volunteers had a significantly longer T1 than both fibrotic and morphologically normal lung in
patients with ILD. T1 of fibrotic lung tissue continued to decrease until 20 min after contrast injection,
whereas morphologically normal lung T1 did not significantly change after 10 min. These results showed a
different contrast enhancement between healthy lung tissue and morphologically normal lung in ILD
patients (figure 3). Therefore, GBCA could be used to identify early fibrotic changes (not yet detectable by
thin-slices MDCT) in morphologically normal lung parenchyma.
KING et al. [48] evaluated the effects of a tailored window setting for lung MRI and gadopentetate
dimeglumine (Magnevist; Bayer, Berlin, Germany) on the visibility of pulmonary abnormalities occurring
in UIP. In this study T1-weighted MRIs were obtained before and after contrast administration and
visualised with conventional window setting and with “MRI lung” window setting chosen to increase the
visibility of lung parenchyma, similar to a lung window setting on thin-slices MDCT. The use of GBCA
significantly improved the detection of honeycombing (sensitivity 59% and specificity 89%), but it did not
influence the detection of ground-glass opacity. The use of a MRI lung window setting improved the
detection of ground-glass opacity both in the contrast-enhanced and unenhanced scans. Moreover, MRI
lung window setting improved the detection of honeycombing in the contrast-enhanced scans.
In the study of HEKIMOĞLU et al. [24], two fast imaging sequences (HASTE and VIBE) were tested with
and without GBCA for evaluating progressive massive fibrosis. Interestingly, post-contrast VIBE imaging
showed the best agreement (ICC 0.999, single measures) with thin-slices MDCT, indicating a better
detection of ILD features after GBCA administration. To date, perfusion imaging with dynamic contrast
enhancement technique has been tested in the aforementioned studies and in studies to assess disease
activity, which will be discussed in the following sections.
Assessment of disease activity
IPF is a chronic fibrotic and progressive disease with restricted therapeutic options. Currently the two
drugs used for IPF are pirfenidone (Roche) and nintedanib (Boehringer Ingelheim), which slow down
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disease progression [49]. Other progressive forms of pulmonary fibrosis, such as collagen vascular
disease-related ILD, are treated with anti-inflammatory drugs. Several on-going trials are currently
recruiting patients with (progressive) pulmonary fibrosis other than IPF including collagen vascular
disease (www.clinicaltrials.gov NCT02999178 and NCT02597933; and DRKS00009822). In this clinical
setting, the ability to assess the disease activity and, in particular, to detect lung areas with active
inflammation and early fibrosis might be a crucial parameter to determine the type of treatment (e.g.
antifibrotic versus anti-inflammatory) and to monitor its efficacy. This ability is lacking with thin-slices
MDCT, which is extremely limited to distinguish active inflammation from fibrosis. In fact, fibrotic lung
tissue with and without active lung inflammation could have similar appearance with ground-glass opacity
and reticulation [50]. Conversely the higher tissue characterisation of MRI could represent an innovative
and noninvasive method to assess disease activity of ILD.
Conventional sequences: single shot, fast spin echo
LUTTERBEY et al. [51] evaluated the feasibility of lung MRI at high magnetic field strengths (3.0T) using a
fat suppressed (Fat-Sat) T2 Fast Spin Echo sequence to assess active versus non-active lung disease in ILD
patients. This sequence is extremely sensitive to fluids. Since inflammation is accompanied by higher water
content in the inflammatory tissue, they hypothesised a higher T2-weighted signal in active inflammatory
lung lesions compared to chronic and fibrotic lung tissue. The results of their study showed that normal
lung tissue appeared long T2 component signal free, that of fibrotic tissue was comparable to the muscle
signal (intermediate signal), while inflammatory tissue showed high T2 (water-like) signal. Signal intensity
was calculated by placing the region-of-interest in multiple lung areas with abnormalities and with
different T2 signal intensity. Thin-slices MDCT was used as a reference standard to correlate
morphological changes. Those lung areas with signal intensity twice higher that of the intermediate-signal
areas were the lung area having the typical features of active ILD disease, such as ground-glass opacity.
These findings were also confirmed by pathological evaluation obtained on lung biopsy specimen.
T2 mapping
BUZAN et al. [52] compared the T2 relaxation time of normal and impaired lung tissue. By using T2




FIGURE 3 T1-contrast enhancement signal characteristics in the fibrotic and normal lung parenchyma pre- and post-contrast injection at ∼5, 10
and 20 min in a 73-year-old female with fibrotic nonspecific interstitial pneumonia. a) Chest magnetic resonance imaging axial reformat
three-dimensional SPGR proton density-weighted pre-contrast. Axial reformats three-dimensional SPGR T1-weighted post-contrast at b) 5 min
and c) 10 min. d) Contrast enhancement subtraction image (10 min image subtracted to pre-contrast). e) Axial maximum slope of increase of
contrast enhancement. f ) Contrast enhancement curves for fibrotic and normal lung at different time-points, Green region of interest in (a) and
arrow in (f ) indicate fibrotic lung tissue, while white region of interest in (a) and arrowhead in (f ) indicate normal lung tissue. Note progressive
contrast enhancement of fibrotic lung with peak at 10 min (arrow), while normal lung has a lower contrast enhancement with signal decay after
the first 5 min (arrowhead).
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honeycombing in UIP and NSIP [52]. T2 sagittal maps were generated using a multi-echo single-shot,
turbo spin echo sequence. They found that the median T2 relaxation time of normal lung was 41 ms and
was significantly shorter than in pathological areas (p<0.001). Moreover, T2 relaxation time was
significantly different (p<0.05) between ground-glass opacity, reticulation and honeycombing with a
median value of 66.5 ms, 74.3 ms and 79.5 ms, respectively. This study demonstrated that T2 relaxation
time tended to increase significantly with progression of fibrotic changes in ILD, the authors explained
that the increase of water-rich tissues and macromolecule fraction in fibrosis leads to increased T2
relaxation time, which depends on water content and its interaction with macromolecules.
Diffusion weighted imaging
DWI is a noninvasive technique for measuring the water diffusion rate within tissue. Water diffusion is
frequently altered in various disease processes and may reflect physiological and morphological
characteristics, such as cell density and tissue viability. DWI has been used for lung cancer imaging [53]
and more recently to detect and quantify inflammation in cystic fibrosis patient with a pulmonary
exacerbation [54]. The latter application is of particular interest for ILD patients because it could be used
as a potential marker of active disease and to monitor treatment response (figure 4) [31]. To date, DWI
has not been tested on ILD patients. Future studies should test feasibility of DWI on ILD patients.
Contrast-enhanced techniques
YI et al. [13] studied the utility of 3.0T contrast-enhanced MRI for differentiating inflammation and
fibrosis predominant lesions in the UIP and NSIP. Contrast-enhanced MRI consisted of T1-weighted
three-dimensional turbo field-echo sequence using an intravenous bolus injection of gadopentetate
dimeglumine (0.2 mL·kg−1 of Magnevist). Enhancement pattern was visually assessed prospectively and
classified into three categories using the dynamic contrast images: pattern 1: early enhancement and
washout with discernible enhancement of peak enhancement at 1 or 3 min; pattern 2: slight enhancement
with no discernible enhancement at a specific time-point throughout dynamic phases; and pattern 3:
delayed persistent enhancement with discernible peak enhancement at 5 or 10 min. Qualitatively analysis
showed that 82% of inflammation-predominant lesions exhibited early enhancement (pattern 1) and that
94% of fibrosis-predominant lesions exhibited slight enhancement (pattern 2) or delayed persistent
enhancement (pattern 3). The frequency of pattern 1 was significantly higher in the
inflammation-predominant lung lesions (82% confidence interval). Quantitative assessment of dynamic
enhanced MRIs were obtained by measuring the mean signal intensity of the lung lesions with
regions-of-interest positioned by a radiologist in correlation to the thin-slices MDCT findings. The
following parameters were evaluated: maximum peak enhancement; time to peak; slope of enhancement;
and extent of washout. Inflammation-predominant lesions sites had higher percentage signal intensity at
1 min, shorter time to peak and faster slope of enhancement than fibrosis-predominant sites. In summary,
qualitative analysis of dynamic T1-weighted three-dimensional turbo field-echo MRIs obtained at 3.0T
proved helpful for differentiating inflammation- and fibrosis-predominant lesions.
GAETA et al. [55] evaluated the gadolinium-enhanced MRI in the assessment of disease activity in 25
consecutive patients with chronic infiltrative lung diseases. They assumed that gadolinium enhancement
might correlate with disease activity, because pulmonary insults inducing lung fibrosis disrupt capillary
endothelium and permit the extravasation of contrast into the interstitial and alveolar spaces. Two
radiologists retrospectively evaluated MRI and analysed the studies for the presence (group 1) or absence
(group 2) of pulmonary lesion enhancement. The presence of enhancement was considered predictive of
active inflammation; the absence of enhancement was considered predictive of inactivity. The presence of
enhanced pulmonary lesions was seen in 14 out of 17 patients with active disease. Negative enhancement
was seen in all eight (100%) patients with inactive disease, and in three (18%) out of 17 patients with active
disease. In both groups the difference was statistically significant (Fisher exact test, p<0.05). These data
showed that the presence of enhancing lesions on gadolinium-enhanced T1-weighted MRI studies may be a
reliable indicator of inflammation and, consequently, potentially influence treatment choice and follow-up.
Phase-contrast MRI
ILD may be complicated by pulmonary hypertension from pulmonary vasospasm due to: hypoxaemia,
pulmonary vasoconstriction and vascular remodelling, vascular destruction associated with progressive
parenchymal fibrosis, vascular inflammation, perivascular fibrosis and thrombotic angiopathy. Although
echocardiography is the mainstay for imaging of the right heart in clinical practice, advances in
velocity-encoded MRI as well as other cardiac magnetic resonance techniques have provided an
opportunity for quantitative and qualitative assessment of haemodynamics in the pulmonary circulation and
identification of right ventricular morphological changes. Phase-contrast MRI combined with cardiac MRI is
now regarded as the reference standard for the assessment of right ventricle structure and function [31].
https://doi.org/10.1183/16000617.0062-2018 8
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FIGURE 4 Diffusion weighted imaging (DWI) at multiple b-values in a 72-year-old female with nonspecific interstitial pneumonia. a) Three-dimensional SPGR proton density-weighted (PD-w)
image, b) two-dimensional fat suppressed PROPELLER T2-weighted image, c–e) DWI at b-values c) 200, d) 400 and e) 800 s·mm−2, and f ) apparent diffusion coefficient (ADC) map. Note
area of inflammation in proton density-weighted image (arrow in a), which has a high T2-weighted signal (arrow in b) and shows signal decay by increasing b-values in the DWI images





















Nowadays, phase-contrast MRI is a standard subset of cardiac MRI protocols. Phase-contrast MRI was tested
on ILD patients to correlate the decrease of pulmonary blood flow detected by phase-contrast MRI
(measured in the main, right and left pulmonary arteries) with the decrease in lung volume and increase of
pulmonary fibrosis calculated by thin-slices MDCT. The study showed that progression of lung fibrosis is
associated with pulmonary blood flow reduction in ILD with or without pulmonary hypertension. It was
speculated that this finding was due to increased resistance in the pulmonary arterioles [56, 57].
Cine MRI
Chest mechanics using MRI has been investigated in several chronic obstructive lung diseases [58, 59]. It
has been shown that diaphragmatic function correlates well with lung function in asthma and chronic
obstructive pulmonary disease patients. Chest mechanics and diaphragm function is also particularly
important in neuromuscular diseases, where diaphragmatic function is monitored to assess treatment
efficacy [60]. To date, however, chest mechanics has not been investigated in ILD patients. Lung fibrosis is
associated with a reduction of the elastic recoil and consequently higher workload for the respiratory
muscles to expand the chest cage, which eventually results in lower lung volumes [2]. Theoretically, disease
progression in fibrotic ILD patients should demonstrate a reduction of diaphragm function. This
information could be used to monitor worsening of lung function in ILD patients and possibly used as a
new outcome measure for prognosis and indication to lung transplantation.
The development of progressive parenchymal fibrosis in ILD patients causes lung restriction as a result of
increased lung stiffness and reduced compliance. Recently, MARINELLI et al. [61] investigated the use of
magnetic resonance elastography in the quantitative assessment of pulmonary fibrosis by comparing
quantitative shear stiffness measurements of lung parenchyma in patients with a diagnosis of ILD and
normal controls. A 1.5 T two-dimensional spin-echo, echo planar imaging magnetic resonance
elastography pulse sequence was utilised to assess absolute lung shear stiffness in 15 patients diagnosed
with ILD and in 11 healthy controls. Lung shear stiffness was evaluated at residual volume and total lung
capacity (TLC). Prior to scanning all patients underwent spirometry. Patients with ILD exhibited an
average shear stiffness of 2.74 kPa at TLC and 1.32 kPa at residual volume. The corresponding values for
healthy individuals were 1.33 kPa and 0.849 kPa, respectively. The difference in shear stiffness between
residual volume and TLC was statistically significant (p<0.001). This study demonstrated that the shear
stiffness in patients with ILD, measured by magnetic resonance elastography, is increased when compared
to healthy individuals at both residual volume and TLC. Because in this study the lung stiffness increases
in ILDs with increasing transpulmonary pressure (i.e. from residual volume to TLC), the most significant
difference in shear stiffness was demonstrated at TLC.
Proposed MRI protocol
Based on the findings in the literature, we have developed a patient-friendly MRI ILD protocol (M-ILD).
Our M-ILD protocol was developed using a 3.0T whole body MRI system (Discovery MR750 3.0T; GE
Healthcare). We use an eight-element phased array cardiac coil with the patient in the supine position and
breathing monitoring using a respiratory belt. ILD patients have problems of hyperpnoea and cannot lie
down for a long time. Therefore, we elaborated a short MRI scan protocol with pre-contrast acquisitions of
∼20 min, followed by a scan break and post-contrast acquisitions at 10 and 20 min. To increase protocol
feasibility, we used commercially available sequences, limiting the use of experimental MRI techniques that
are only available in the research setting. The proposed M-ILD protocol is summarised in supplementary
table 2 with optional sequences for a research setting.
For morphological analysis, we proposed a three-dimensional proton density-weighted (PD-w) sequence
(3D SPGR), and a two- and three-dimensional T2-w acquisition (2D fat suppressed (FS) PROPELLER and
3D CUBE T2 FS).
For functional imaging we used a 3D SPGR T2* multi-echo sequence both in inspiration and expiration to
generate T2* maps. T2* maps could be used to assess lung fibrosis and ventilation (figure 5). We also
added a 2D DWI multi b-value acquisition to assess lung inflammation. Finally, we added 3D SPGR FS
sequences before and after injection of 0.2 mmol·kg−1 of gadobenate dimeglumine (MultiHance; Bracco,
Milan, Italy) at 10 and 20 min to evaluate late enhancement of fibrotic lung tissue. Post-processing
analysis of the data was also performed with commercially available software on the AW Server 2.0
platform (GE Healthcare).
We aimed to test our M-ILD protocol in a large multicentre cohort study in patients with ILD. For a
multicentre study, robust and feasible MRI techniques are needed. The M-ILD protocol has been
developed with commercially available sequences, which can be implemented with all MRI brands. Image
quality standardisation between centres can be achieved using a dedicated lung-MRI phantom [62].
However, some of the proposed sequences are still high demanding and complex techniques, such as
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hyperpolarised gas-MRI, oxygen-enhanced MRI, T1/T2 mapping that could require further refinement
before large scale application.
Future directions
The role of thin-slices MDCT to evaluate progression and treatment response of ILD is still debated,
because of the poor reproducibility of visual score for several parenchymal abnormalities and lack of
specific outcome measures to evaluate response to treatment.
Although image resolution of MRI does not yet match that of thin-slices MDCT, MRI could play an
important role for functional imaging in patients with ILD. In particular, the ability of MRI to detect and
quantify inflammatory changes using different tissue signal weighting could be used to monitor treatment
efficacy of new ILD drugs. MRI could differentiate between active inflammatory and fibrotic changes thus
guiding targeted therapy in patients with ILD. These hypotheses need to be proved in future studies in
order to determine whether MRI could have a role in the management of patients with ILD. Functional
MRI could fill the diagnostic gaps still present in thin-slices MDCT imaging of ILD patients.
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